Apyx medical corporation reports first quarter 2023 financial results and updates full year 2023 financial outlook

Clearwater, fla.--(business wire)--apyx medical corporation (nasdaq:apyx) (the “company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as renuvion®, today reported financial results for its first quarter ended march 31, 2023, and updated financial expectations for the full year ending december 31, 2023. first quarter 2023 financial summary: total revenue of $12.1 million, down 3% year-over-year. advanced energy revenue of $9.7 million, down 10.
APYX Ratings Summary
APYX Quant Ranking